Source-grounded facts extracted from BIOMARIN PHARMACEUTICAL INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIOMARIN PHARMACEUTICAL INC shareholders approved Approval of an Amendment to the 2017 Equity Incentive Plan at the 2026-04-07 meeting.
“Proposal 4: Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes: For Against Abstain Broker Non-Votes 158,561,867 5,480,380 152,003 11,619,042 Based on the votes set forth above, BioMarin’s stockholders approved the Plan Amendment.”
BIOMARIN PHARMACEUTICAL INC shareholders approved Advisory Vote on the Compensation of Named Executive Officers at the 2026-04-07 meeting.
“Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement, received the following votes: For Against Abstain Broker Non-Votes 142,742,800 21,287,767 163,683 11,619,042 Based on the votes set forth above, BioMarin’s stockholders approved, on an advisory basis, the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement.”
BIOMARIN PHARMACEUTICAL INC shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-04-07 meeting.
“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin’s independent registered public accounting firm for the fiscal year ending December 31, 2026, as set forth in the Proxy Statement, received the following votes: For Against Abstain 170,867,335 4,850,526 95,431 Based on the votes set forth above, BioMarin’s stockholders ratified the selection of KPMG LLP as BioMarin’s independent registered public accounting firm to serve for the year ending December 31, 2026.”
BIOMARIN PHARMACEUTICAL INC shareholders approved Election of Directors at the 2026-04-07 meeting.
“Item 5.07 Submission of Matters to a Vote of Security Holders. A total of 193,270,028 shares of common stock were entitled to vote as of April 7, 2026, the record date for the Annual Meeting. There were 175,813,292 shares of common stock present in person or represented by proxy at the Annual Meeting at which the stockholders were asked to vote on four proposals, each of which is described in more detail in the Proxy Statement. Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal. Proposal 1: Election of Directors Directors Elected For Against Abstain Broker Non-Votes Elizabeth M. Anderson 152,826,855 11,325,400 41,995 11,619,042 Barbara W. Bodem 162,832,241 796,989 565,020 11,619,042 Ian T. Clark 144,380,101 19,160,530 653,619 11,619,042 Athena Countouriotis 162,326,065 1,823,399 44,786 11,619,042 Willard Dere 161,112,606 2,973,541 108,103 11,619,042 Mark J. Enyedy 161,113,325 3,032,040 48,885 11,619,042 Alexander Hardy 163”
BIOMARIN PHARMACEUTICAL INC reported the first quarter ended March 31, 2026 results: revenue $766 million, net income $106 million. Guidance raised.
“Total Revenues for the first quarter of 2026 were $766 million”
BIOMARIN PHARMACEUTICAL INC incurred credit facility of $2.0 billion senior secured term loan "B" facility, $800.0 million senior secured term loan "A" facility, and $600.0 mil with Citibank, N.A., as administrative agent and collateral agent at Term SOFR plus an applicable margin; for Term B Loans, 1.75% per annum for Term maturing Term Loan B Facility matures on seventh anniversary of Closing Date; Term Loan A Facility and Revolving Facility each mature on fifth anniversary of Closing Dat.
“as administrative agent and collateral agent (in such capacities, the “ Administrative Agent ” and the “ Collateral Agent ,” respectively). The Credit Agreement provides for a $2.0 billion senior secured term loan “B” facility (the “ Term Loan B Facility ” and the loans thereunder, the “ Term B Loans ”), a $800.0 million senior secured term loan “A” facility (the “”
BIOMARIN PHARMACEUTICAL INC entered into Merger Agreement with Amicus valued at Amicus merged with and into Merger Sub with Amicus continuing as the surviving corporation and as a (effective 2026-04-27).
“ursuant to the terms of the Merger Agreement, Amicus merged with and into Merger Sub (the “ Merger ”) with Amicus continuing as the surviving corporation and as a wholly owned subsidiary of BioMarin.”
BIOMARIN PHARMACEUTICAL INC incurred senior notes of $850 million aggregate principal amount at 5.500% maturing 2026.
“On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.”
BIOMARIN PHARMACEUTICAL INC entered into Indenture with U.S. Bank Trust Company, National Association, as trustee valued at $850 million aggregate principal amount (effective 2026-02-12).
“On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.”
BIOMARIN PHARMACEUTICAL INC entered into Agreement and Plan of Merger with Amicus Therapeutics, Inc. valued at $14.50 per Share in cash (effective 2025-12-19).
“On December 19, 2025, BioMarin Pharmaceutical Inc., a Delaware corporation (“ BioMarin ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Amicus Therapeutics, Inc. (the “ Company ” or “ Amicus ”), and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of BioMarin (“ Merger Sub ”), providing for the merger of Merger Sub with and into Amicus (the “ Merger ”), with Amicus surviving the Merger as a wholly owned subsidiary of BioMarin.”
BIOMARIN PHARMACEUTICAL INC: Approved and adopted Amended and Restated Bylaws, effective February 25, 2025, with updates to advance notice provisions, director election standards, officer removal, and administrative updates (effective 2025-02-25).
“On February 25, 2025, the Board of Directors (the "Board") of BioMarin Pharmaceutical Inc. (the "Company") approved and adopted the Company's Amended and Restated Bylaws (as so amended, the "Amended Bylaws"), effective as of February 25, 2025.”
Timothy P. Walbert was appointed as Director at BIOMARIN PHARMACEUTICAL INC.
“the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) increased the size of the Board from eleven to twelve members and appointed Timothy P. Walbert to the Board, to be effective February 24, 2025.”
BIOMARIN PHARMACEUTICAL INC announced a restructuring with charges of approximately $30 - $35 million (approximately 225 employees).
“The Company estimates that it will incur aggregate pre-tax charges representing one-time cash expenditures for severance and other employee termination benefits of approximately $30 - $35 million, of which the majority is expected to be incurred during the second half of 2024. Impacted employees were notified by August 28, 2024, and workforce reductions are”
Greg Friberg was appointed as Executive Vice President, Chief Worldwide Research and Development Officer at BIOMARIN PHARMACEUTICAL INC.
“He will continue in his current role until Dr. Greg Friberg assumes the position of Executive Vice President, Chief Worldwide Research and Development Officer, which is expected on September 30, 2024.”
Henry J. Fuchs retired as Executive Vice President, Chief Worldwide Research and Development Officer at BIOMARIN PHARMACEUTICAL INC.
“On August 16, 2024, Dr. Henry J. Fuchs advised BioMarin Pharmaceutical Inc. (the “Company”) that he has elected to retire from the Company effective March 3, 2025 (the “Retirement Date”).”
BIOMARIN PHARMACEUTICAL INC announced a restructuring with charges of approximately $15 - $20 million affecting research and development programs (approximately 170 employees).
“In connection with the discontinuation of certain research and development programs, on May 9, 2024, the Company committed to a plan to reduce its global workforce by approximately 170 employees. The Company estimates that it will incur aggregate pre-tax charges of approximately $15 - $20 million during the second quarter of 2024, representing one-time cash expenditures for severance and other employee termination benefits.”
BIOMARIN PHARMACEUTICAL INC reported first quarter ended March 31, 2024 results: revenue $648.8 million, net income $88.7 million, EPS $0.46. Guidance reaffirmed.
“Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Record Financial Results for the First Quarter 2024 First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earnings per Share of $0.71 (+18% Y/Y) VOXZOGO ® Net”
BIOMARIN PHARMACEUTICAL INC reported fourth quarter and full year ended December 31, 2023 results: revenue $646.2 million, net income $20.4 million, EPS $0.11. Guidance reaffirmed.
“plans and convertible debt in periods when they are dilutive under Non-GAAP. nm Not meaningful Financial Highlights: • Total Revenues for the fourth quarter of 2023 were $646.2 million, an increase of 20% compared to the same period in 2022. The increase in Total Revenues was primarily attributed to higher VOXZOGO sales volume driven by new patients initiating”
Jeffrey Ajer departed as Executive Vice President and Chief Commercial Officer at BIOMARIN PHARMACEUTICAL INC.
“On January 11, 2024, BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) announced that Mr. Jeffrey Ajer would step down as the Company’s Executive Vice President and Chief Commercial Officer, effective July 1, 2024.”
BIOMARIN PHARMACEUTICAL INC entered into Cooperation Agreement with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, “Elliott”) (effective 2023-12-20).
“On December 20, 2023, BioMarin Pharmaceutical Inc. (the “Company”) announced that it had entered into a Cooperation Agreement (the “Cooperation Agreement”) with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, “Elliott”)”
Mark Enyedy was appointed as director at BIOMARIN PHARMACEUTICAL INC.
“On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.”
Athena Countouriotis was appointed as director at BIOMARIN PHARMACEUTICAL INC.
“On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.”
Barbara Bodem was appointed as director at BIOMARIN PHARMACEUTICAL INC.
“On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.”
Richard A. Meier was appointed as Chair of the Board at BIOMARIN PHARMACEUTICAL INC.
“Richard A. Meier, BioMarin’s lead independent director, will assume the role of Chair of the Board, effective December 1, 2023.”
Alexander Hardy was appointed as President and Chief Executive Officer at BIOMARIN PHARMACEUTICAL INC.
“the Company announced the appointment of Alexander Hardy, age 55, to serve as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of December 1, 2023”
Jean-Jacques Bienaimé retired as President, Chairman and Chief Executive Officer at BIOMARIN PHARMACEUTICAL INC.
“Jean-Jacques Bienaimé will retire as the Company’s President, Chairman and Chief Executive Officer effective as of close of business on November 30, 2023”
BIOMARIN PHARMACEUTICAL INC updated its full-year 2023 guidance (reaffirmed).
“"Results in the quarter drove double-digit revenue growth year-over-year and supports BioMarin’s full-year 2023 revenue and profitability objectives, set at the beginning of the year,"”
BIOMARIN PHARMACEUTICAL INC reported third quarter ended September 30, 2023 results: revenue $581.3 million, net income $40.4 million, EPS $0.21.
“facilitate patient access, setting the stage for meaningful uptake of ROCTAVIAN in 2024.” Third Quarter Financial Highlights: • Total Revenues for the third quarter of 2023 were $581.3 million, an increase of 15% compared to the same period in 2022. The increase in Total Revenues was primarily attributed to the following: ◦ higher VOXZOGO sales volume due to new”
BIOMARIN PHARMACEUTICAL INC updated its the six months and second quarter ended June 30, 2023 guidance (reaffirmed).
“On July 31, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its second quarter ended June 30, 2023.”
BIOMARIN PHARMACEUTICAL INC shareholders approved Approval of an Amendment to the 2017 Equity Incentive Plan.
“Proposal 5: Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes: For Against Abstain Broker Non-Votes 138,471,429 17,279,619 109,949 10,893,446”
BIOMARIN PHARMACEUTICAL INC shareholders approved Advisory Vote on the Compensation of Named Executive Officers.
“Proposal 4: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement, received the following votes: For Against Abstain Broker Non-Votes 129,779,900 24,543,430 1,537,667 10,893,446”
BIOMARIN PHARMACEUTICAL INC shareholders approved Advisory Vote on Frequency of Advisory Vote on the Compensation of Named Executive Officers.
“Proposal 3: Advisory Vote on Frequency of Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote on the frequency of the advisory vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement, received the following votes: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 154,888,549 50,595 876,495 45,358 10,893,446”
BIOMARIN PHARMACEUTICAL INC shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-12-31 meeting.
“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin’s independent registered public accounting firm for the fiscal year ending December 31, 2023, as set forth in the Proxy Statement, received the following votes: For Against Abstain 159,510,686 7,133,289 110,468”
BIOMARIN PHARMACEUTICAL INC shareholders approved Election of Directors.
“Proposal 1: Election of Directors Directors Elected Vote For Withheld Broker Non-Votes Mark J. Alles 132,590,721 23,270,276 10,893,446 Elizabeth McKee Anderson 143,554,881 12,306,116 10,893,446 Jean-Jacques Bienaimé 142,990,946 12,870,051 10,893,446 Willard Dere, M.D. 148,341,372 7,519,625 10,893,446 Elaine J. Heron, Ph.D. 145,753,472 10,107,525 10,893,446 Maykin Ho, Ph.D. 154,901,420 959,577 10,893,446 Robert J. Hombach 149,263,399 6,597,598 10,893,446 V. Bryan Lawlis, Ph.D. 150,808,310 5,052,687 10,893,446 Richard A. Meier 151,345,310 4,515,687 10,893,446 David E.I. Pyott, M.D. (Hon.) 147,242,636 8,618,361 10,893,446 Dennis J. Slamon, M.D., Ph.D. 154,624,428 1,236,569 10,893,446”
BIOMARIN PHARMACEUTICAL INC updated its first quarter ended March 31, 2023 guidance (raised).
“On April 26, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March 31, 2023.”
BIOMARIN PHARMACEUTICAL INC updated its fourth quarter and full year ended December 31, 2022 guidance (reaffirmed).
“On February 27, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its fourth quarter ended December 31, 2022. The Company’s press release issued on February 27, 2023 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.”
BIOMARIN PHARMACEUTICAL INC reported the year ended December 31, 2022 results: revenue approximately $2.09 billion in total revenues (unaudited).
“based on preliminary results the Company estimates that it generated approximately $2.09 billion in total revenues (unaudited) for the year ended December 31, 2022”
BIOMARIN PHARMACEUTICAL INC: Amended and restated bylaws to update provisions related to stockholder meetings, proxy rules, and other administrative changes (effective 2022-12-15).
“On December 15, 2022, the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) approved and adopted the Company’s Amended and Restated Bylaws (as so amended, the “Amended Bylaws”), effective as of December 15, 2022.”
Erin Burkhart was appointed as Group Vice President, Chief Accounting Officer at BIOMARIN PHARMACEUTICAL INC.
“On May 05, 2022., BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) announced the appointment of Erin Burkhart as BioMarin’s Group Vice President, Chief Accounting Officer, effective May 2, 2022.”
Mark J. Alles was appointed as Director at BIOMARIN PHARMACEUTICAL INC.
“appointed Mark J. Alles to the Board and to the Audit Committee of the Board, to be effective January 1, 2022.”
Brian Mueller was appointed as principal accounting officer at BIOMARIN PHARMACEUTICAL INC.
“In the event that the Company has not appointed a successor on or prior to the Effective Date, Brian Mueller, BioMarin’s Executive Vice President, Finance and Chief Financial Officer, will serve as the Company’s principal accounting officer from the Effective Date until Ms. Acosta’s successor is appointed.”
Andrea Acosta resigned as Group Vice President, Chief Accounting Officer, and principal accounting officer at BIOMARIN PHARMACEUTICAL INC.
“On October 29, 2021, Andrea Acosta, the Group Vice President, Chief Accounting Officer, and principal accounting officer of BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) notified BioMarin of her decision to resign, effective as of January 28, 2022 (the “Effective Date”), in order to pursue another career opportunity.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.